lifestyle.timesla.com

Author: Protara Therapeutics

Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

March 10, 2026
TARA-002 Demonstrates 68% Complete Response Rate at Six Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

February 23, 2026
Protara Therapeutics to Participate in Upcoming Investor Conferences

February 19, 2026
Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 10, 2026
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

January 22, 2026